Drew Weissman, M.D., Ph.D.

faculty photo
Professor of Medicine
Department: Medicine
Graduate Group Affiliations

Contact information
410B Hill Pavilion
380 S University Ave.
Philadelphia, PA 19104
Office: (215) 573-8491
Education:
B.A., M.A. (Biochemistry/Enzymology)
Brandeis University, 1981.
M.D. Ph.D. (Immunology/Microbiology)
Boston University, 1987.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research and gene therapy. There are three main projects in his laboratory. The first project began through the use of mRNA encoding antigen as a delivery system to load dendritic cells to promote broad immune responses as part of a vaccine. This project has expanded to include basic studies of RNA immunogenicity and translation and the development of applications for gene therapy. The second project develops new HIV envelope immunogens that can induce broad responses and cross-reactive neutralizing antibodies. The third project continues previous studies that identified a protein found on DC, macrophages, and epithelial cells that binds HIV envelope with high affinity. The main focus of this project is testing whether this and related molecules function in vivo to promote HIV genital tract infection.

Selected Publications

Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V.: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun 12: 613, Jan 2021.

Riley RS, Kashyap MV, Billingsley MM, White B, Alameh MG, Bose SK, Zoltick PW, Li H, Zhang R, Cheng AY, Weissman D, Peranteau WH, Mitchell MJ.: Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv 7: eaba1028, Jan 2021.

Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.: Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines (Basel) 9: 65, Jan 2021.

Martinez DR, Schaefer A, Leist SR, De la Cruz G, West A, Atochina-Vasserman EN, Parks R, Barr M, Li D, Yount B, Saunders KO, Weissman D, Haynes BF, Montgomery SA, Baric RS.: Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice. bioRxiv ioRxiv, 2021.

Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H, Edwards RJ, Gobeil S, Barr M, Mansouri K, Alam SM, Sutherland LL, Cai F, Sanzone AM, Berry M, Manne K, Kapingidza AB, Azoitei M, Tse LV, Scobey TD, Spreng RL, Rountree RW, DeMarco CT, Denny TN, Woods CW, Petzold EW, Oguin TH, Sempowski GD, Gagne M, Douek DC, Tomai MA, Fox CB, Seder R, Wiehe K, Weissman D, Pardi N, Acharya P, Andersen H, Lewis MG, Moore IN, Montefiori DC, Baric RS, Haynes BF.: SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys. bioRxiv ioRxiv, 2021.

Lederer K, Castaño D, Gómez Atria D, Oguin TH 3rd, Wang S, Manzoni TB, Muramatsu H, Hogan MJ, Amanat F, Cherubin P, Lundgreen KA, Tam YK, Fan SHY, Eisenlohr LC, Maillard I, Weissman D, Bates P, Krammer F, Sempowski GD, Pardi N, Locci M.: SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity mmunity: 1281-1295, Dec 2020.

Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche CC, Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi N, Hengartner N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya P, Haynes BF, Korber B, Montefiori DC: D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host Microbe S1931-3128(20): 30634, Dec 2020.

LaTourette PC 2nd, Awasthi S, Desmond A, Pardi N, Cohen GH, Weissman D, Friedman HM.: Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine. Vaccine 38: 7409-7413, Nov 2020.

Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH 3rd, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tombácz I, Arwood L, Nachbagauer R, Karikó K, Greenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, Lin PJC, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Andersen H, Eisenlohr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N.: A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity 53: 724-732, Oct 2020.

Pardi N, Hogan MJ, Weissman D.: Recent advances in mRNA vaccine technology. Curr Opin Immunol. 65: 14-20, Aug 2020.

back to top
Last updated: 04/25/2021
The Trustees of the University of Pennsylvania